Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from GlaxoSmithKline ( (GSK) ).
On 17 March 2026, GSK plc repurchased 732,112 of its ordinary shares, with prices ranging between 2,002p and 2,036p and a volume-weighted average price of 2,016.45p, acting via BNP Paribas under its non‑discretionary buyback agreement. The shares will be held in treasury, bringing total treasury stock to 251,176,615 shares, or 6.18% of voting rights, and leaving 4,064,994,150 shares in issue, a move that continues GSK’s ongoing capital management programme and marginally increases earnings per share for remaining investors.
Since the buyback programme’s start on 17 February 2026, GSK has bought 11,285,521 shares in aggregate, signalling sustained management confidence in the company’s valuation and balance-sheet strength. The updated total voting rights figure of 4,064,994,150 will be used by shareholders to assess whether they must disclose changes in ownership under U.K. transparency rules, underscoring the governance implications of the transaction for institutional investors and other major holders.
The most recent analyst rating on (GSK) stock is a Hold with a $58.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.
Spark’s Take on GSK Stock
According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.
The score is supported primarily by resilient fundamentals (strong profitability and positive cash generation) and a constructive earnings outlook with higher dividend guidance and continued specialty/HIV momentum. These positives are tempered by leverage and recent revenue/FCF volatility, while technically the stock is in a strong uptrend but looks overbought, raising near-term pullback risk.
To see Spark’s full report on GSK stock, click here.
More about GlaxoSmithKline
GSK plc is a global biopharmaceutical company based in London, focused on developing, manufacturing and marketing prescription medicines, vaccines and consumer healthcare products. The group operates across multiple therapeutic areas and derives the bulk of its revenues from patented pharmaceuticals and vaccines, with a primary listing on the London Stock Exchange.
Average Trading Volume: 5,252,149
Technical Sentiment Signal: Buy
Current Market Cap: $107.6B
Find detailed analytics on GSK stock on TipRanks’ Stock Analysis page.